Last reviewed · How we verify
STSA-1002 injection
STSA-1002 injection is a monoclonal antibody targeting the PD-1 receptor.
STSA-1002 injection is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | STSA-1002 injection |
|---|---|
| Sponsor | Staidson (Beijing) Biopharmaceuticals Co., Ltd |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, STSA-1002 injection blocks the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response. This results in the killing of cancer cells and the slowing of tumor growth.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
- Cough
- Dyspnea
- Headache
- Musculoskeletal pain
- Arthralgia
Key clinical trials
- To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome (PHASE3)
- To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome (PHASE1, PHASE2)
- A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects (PHASE1)
- The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects (PHASE1)
- The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects (PHASE1)
- A Study of STSA-1002 in Healthy Subjects (PHASE1)
- The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |